Science · 2021 · 366 citations · 44 references
PharmacyMedicinal ChemistryMolecular BiologyDrug DesignDrug DiscoveryStructural BiologyAllosteric Drug DesignAntiviral PharmacologyEnzyme InhibitionStructure-based RepurposingHigh-throughput CrystallographyRepurposing LibrariesSars-cov-2 InfectionStructure-based Allosteric Drug DesignTreatment Of Coronavirus InfectionsViral Protease InhibitionViral Proteases
A large-scale screen to target SARS-CoV-2 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome is initially expressed as two large polyproteins. Its main protease, M pro , is essential to yield functional viral proteins, making it a key drug target. Günther et al. used x-ray crystallography to screen more than 5000 compounds that are either approved drugs or drugs in clinical trials. The screen identified 37 compounds that bind to M pro . High-resolution structures showed that most compounds bind at the active site but also revealed two allosteric sites where binding of a drug causes conformational changes that affect the active site. In cell-based assays, seven compounds had antiviral activity without toxicity. The most potent, calpeptin, binds covalently in the active site, whereas the second most potent, pelitinib, binds at an allosteric site. Science , this issue p. 642
44
Features and development of <i>Coot</i>
Paul Emsley, Bernhard Lohkamp, W. G. Scott et al. · Acta Crystallographica Section D Biological Crystallography · 2010 · 29.6K citations · Full text
Wolfgang Kabsch · Acta Crystallographica Section D Biological Crystallography · 2010 · 16.9K citations · Full text
Dorothée Liebschner, Pavel V. Afonine, Matthew L. Baker et al. · Acta Crystallographica Section D Structural Biology · 2019 · 7.4K citations · Full text
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Zhenming Jin, Xiaoyu Du, Yechun Xu et al. · Nature · 2020 · 4.5K citations · Full text